The prognostic value of p53 mutation in pediatric marrow hypoplasia
© Abo-Elwafa et al; licensee BioMed Central Ltd. 2011
Received: 9 April 2011
Accepted: 30 June 2011
Published: 30 June 2011
The tumor suppressor gene p53 is involved in the control of cell proliferation, particularly in stressed cells. p 53 gene mutations are the most frequent genetic event found in human cancers. Fanconi Anemia (FA) is the most common representative of inherited bone marrow failure syndromes (IBMFS) with a leukemic propensity. P 53 DNA alteration has not been studied before in Egyptian children with FA.
Patients and methods
we investigated p53 mutation in the bone marrow and peripheral blood of forty children, FA (n = 10), acquired aplastic anemia (AAA) (n = 10), and immune thrombocytopenia (ITP) as a control (n = 20), using real-time PCR by TaqMan probe assay
Mutation of p53 gene was demonstrated in the BM of 90% (9/10) of children with FA, compared to 10% (1/10) in AAA (p < 0.001), while, no p53 DNA mutation was seen in the control group. A positive correlation between DNA breakage and presence of p53 mutation was seen in FA (p < 0.02, r0.81).
mutation of p53 gene in hypoplastic marrow especially FA may represent an early indicator of significant DNA genetic alteration with cancer propensity.
Patients with IBMFS are at increased risk of malignant transformation, possibly due to cell cycle deregulation as marked by the over expression of cell cycle markers as p53 and Ki-67 [1, 2]. Fanconi's anemia (FA), the most common disorder of IBMFS, is a rare autosomal recessive disorder (prevalence of 1-5 per million) with bone marrow failure, developmental anomalies, and predisposition to leukemia and solid tumors [3–5].
The p53 gene plays a major role in cell-cycle regulation, particularly in the presence of a genetic alteration in DNA, a critical step for the initiation of leukemogenesis .
In healthy humans, the p53 protein is continually produced and degraded in the cell. However, it becomes activated in response to multiple types of stresses, which include DNA damage, oxidative stress, osmotic shock, ribonucleotide depletion and deregulated oncogene expression . More than 50% of human tumors contain a mutation or a deletion in the p53 gene. Increasing the expression of p53 gene, which is a tumour suppressor gene involved in the apoptotsis, and the control of cell proliferation may be a good way to treat tumors or prevent them from spreading. Thus, restoring endogenous p53 function as the use of gene therapy holds a lot of promise in future treatment of malignancies [8–10].
Since p53 is not over expressed in the BM of hematologically normal individuals [11, 12]. We hypothesized that DNA damage and cancer predisposition in BM failure disorders could be related to p53 gene alterations. We studied the expression of p53 mutation, as a marker of cell cycle dysregulation, in BM of children with FA as well as children with AAA.
Subjects and Methods
Study design and populations
the study was approved by the Ethical Committee of Clinical Pathology Dept., and Pediatric Dept., Sohag University and Clinical Pathology Dept., Suez Canal University, during the period from April 2007 to June 2010. The study groups included 20 child (9 males and 11 females) with aplastic anemia some of them with congenital malformations (two brothers the old one is 11 years old at the time of sampling he had short stuttered, microcephally, brown skin pigmentation, the younger is 5 years old has extra thumb, girl from another family her age is 12 years, also she had short stuttered, microcephally, brown skin pigmentation and twins boys from another family, they had short stuttered, microcephally, brown skin pigmentation, one of them diagnosed AML at date of presentation ) and other 20 child with ITP (7 males and 13 females) as a control. The age of children at presentation in the study ranged from 4 to 14 years. They were visiting the Hematology Outpatient Clinic, Pediatric Department, Sohag University Hospital. Family history was recorded in pre-designed proforms and a detailed pedigree was taken in each case. Informed consent was taken from the patients or/and their parents in case of younger. All patients in the study and the control groups were subjected to clinical examination laboratory investigations including peripheral hemogram, bone marrow aspiration (BMA). Trephine bone marrow biopsy (BMB) for cases with marrow hypoplasia. Mytomycin C (MMC) stress test and detection of p53 gene mutation were done in all patients of the study and the control groups.
All the study populations were subjected to:
- Routine investigations (random blood sugar, renal function tests and liver function testes on CX-9 Beckman - coulter., France ).
- Complete blood count (Cell Dyne - 2700, Abbott Lab., USA).
- Assessment of BM cellularity:
- Diagnosis of hereditary aplastic anemia (FA) was done in Sohag University Hospital, Pediatric and Clinical Pathology Department depending on personal and family history, physical examination, peripheral blood, bone marrow and MMC test.
- Detection of p53 gene mutation: was performed in Suiz Canal University Hospital, Clinical Pathology Dept., p53 DNA was extracted from BM samples using the AxyPrep blood genomic DNA Miniprep kit according to manufacturer's instructions (AXYGEN Biosciences, CA, USA). p53 DNA amplification was performed by real-time PCR using TaqMan probe technique in a total volume of 100 μl that included: 10 × Buffer (10 μL), dNTPs Mix 200 nM (2 μL), Forward primer (5'-CCCTGTGCAGCTGTGGGTTG-3') 900 nM (10 μL), Reverse primer (5'-ATGGCCATGGTGCGGAC-3') 900 nM (10 μL), TaqMan Probe (5'-FAM-CCAACCCC CGCCCGGCA-TAMRA-3') 300 nM (10 μL), Hot Start Taq polymerase 2.5 U (0.5 μL), MgCl2 100 mM (5 μL), H2O (42.5 μL), and p53 DNA template (10 μL). PCR amplification was done in Rotor-Gene™ 6000 real-time rotary analyzer (Corbett Research Pty Ltd, Mortlake, NSW, Australia) using the following protocol: (95°C for 7 min) for one cycle, followed by a three-step program: (96°C for 45 Sec), (56°C for 1 min) and, (72°C for 30 Sec) for 40 cycles. And,(30° for 10 sec) for one cycle. (N.B primers, Taqman probe, and master mix were provided by Bioron GmbH, Germany).
Values were expressed as mean ± S.D and percentages as appropriate. t-test was used for peripheral blood variables.p53 was compared between groups using Fisher exact test.
Study population characteristics
(n = 10)
(n = 10)
(n = 20)
Age (yrs) (mean ± SD)
8.8 ± 2.2 **
4.7 ± 2.5
10.5 ± 2.1
No specific findings
Regarding the age, FA children are the youngest one at time of presentaion comparing to AAA and ITP (p < 0.001). Sex distribution is equal in FA (50% for both sex), in AAA is (40% males, 60% females), and in ITP the females are predominant (35% males, 65% females).
Peripheral hemogram and bone marrow variables in the studied groups
(n = 10)
(n = 10)
(n = 20)
Peripheral blood (mean ± S.D)
2.4 ± 0.6 **
3.3 ± 0.45 **
8.05 ± 0.85
- TLC (× 109/L)
8.4 ± 0.9 *
9.1 ± 0.5 *
11.3 ± 0.55
- Hb (g/dl)
102.4 ± 6.3 **
79.4 ± 3.5
83.3 ± 7.8
46.1 ± 8.4 **
110.5 ± 12.0
10.7 ± 2.1 **
- Platelets (× 109/L)
Increase megakar -yocytes
Cellularity (no, %)
- Hypocellular (grades 1, 2, 3)
- Normal (grade 4)
- Hypercellular (grades 5, 6)
Mytomycin C stress test
(n = 10)
(n = 10)
(n = 20)
p53 gene expression by real-time PCR
(n = 10)
(n = 10)
(n = 20)
BM p53 DNA:
DNA breakage and p53: a positive correlation between DNA breakage and p53 mutation was demonstrated in FA patients (p < 0.02, r0.81).
p53 protein over expression in IBMFS may represent an early indicator of significant DNA genetic alteration, which is a crucial step in the process of leukemogenesis. Thus, up regulation p53 mutation gene in our FA patients may reflect a state of reaction to cell stress mostly related to DNA damage as previously reported . This activation was explained previously by a drastic increase in the half-life of the p53 protein, leading to a quick accumulation of p53 in stressed cells .
P53 mutation was not expressed in most AAA patients (90%) and all control group patients (ITP) (100%) as previously described . To ensure that cells under non-stressed conditions (as in AAA and control group) are able to grow, p53 sets up a negative feedback loop by inducing a protein called Mdm2 . Mdm2 is able to both inhibit the transcriptional regulation by p53  and, degrade it thus, maintaining p53 inactive until it is required [18–20].
Expression p 53mutation was significantly up regulated in the marrow samples of FA patients (80%). This probably reflected a functional up-regulation of p53 gene to provide additional protection for cells with damaged and potentially hazardous DNA. Apart from two FA patients who showed no expression of p53 mutation in the BM, a good concordance between p53 mutation gene expression and FA was observed. Of note is that these two patients had moderate DNA breakage points and normal BM cellularity. Despite the small number of patients, which, is a limitation of this study, we conclude that FA in Egyptian children is associated with an up regulation of p53 gene mutation which could explain the tendency of those patients to develop malignancies, on the other hand the AAA, only one case (10%) showed the expression of the mutant p53, this case has a severe hypoplastic marrow which postulate the possible oncogenic cause in AAA. However, future studies on larger population are warranted .
List of Abbreviations and symbols
Acquired Aplastic Anemia
Bone Marrow Aspiration
Bone Marrow Biopsy
Immune Thrombocytopenic Purpura
Mytomycin C test
Fischer exact test, *: Significant p-value, **: Highly Significant p-value
to all members of molecular biology unit Clinical Pathology Dept., Suiz Canal Univeristy
- Al-Rahawn MM, Alter BP, Bryant BJ, Elghetany MT: Bone marrow cell cycle markers in inherited bone marrow failure syndromes. Leuk Res. 2008, 32 (12): 1793-9. 10.1016/j.leukres.2008.05.020.View Article
- Rosenberg PS, Greene MH, Alter BP: Cancer incidence in persons with fanconi anemia. Blood 1. 2003, 101 (3): 822-6.View Article
- Moldovan George-Lucian, Andrea Alan: How fanconi anemia pathway guard the genome, National center for biotechnology. Annu Rev Genet. 2009, 43: 223-249. 10.1146/annurev-genet-102108-134222.PubMed CentralView ArticlePubMed
- Xue Y, Li Y, Guo R, Ling C, Wang W: FANCM of the Fanconi anemia core complexis required for both monoubiquitination and DNA repair. Hum Mol Genet. 2008, 17: 1641-52. 10.1093/hmg/ddn054.PubMed CentralView ArticlePubMed
- Alter BP, Giri N, Savage SA, Rosenberg PS: Cancer in dyskeratosis congenita 25. Blood. 2009, 113 (26): 6549-57. 10.1182/blood-2008-12-192880.PubMed CentralView ArticlePubMed
- Elghetany MT, Alter BP: p53 protein overexpression in bone marrow biopsies of patients with Shwachman-Diamond syndrome has a prevalence similar to that of patients with refractory anemia. Arch Pathol Lab Med. 2002, 126 (4): 452-5.PubMed
- Anker P, Mulcahy H, Chen XQ, Stroun M: Detection of circulating tumor DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev. 1999, 18: 65-73. 10.1023/A:1006260319913.View ArticlePubMed
- Wang W: A major switch for the Fanconi anemia DNA damage-response pathway. Nat Struct Mol Biol. 2008, 15: 1128-30. 10.1038/nsmb1108-1128.View ArticlePubMed
- Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, Lu X, Soron G, Cooper B, Brayton C, Hee Park S, Thompson T, Karsenty G, Bradley A, Donehower LA: p53mutant mice that display early ageing-associated phenotypes. Nature. 2002, 415 (6867): 45-53. 10.1038/415045a.View ArticlePubMed
- Ventura A, Kirsch DG, Mclaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T: Restoration of p53 function leads to tumor regression in vivo. Nature. 2007, 445 (7128): 661-5. 10.1038/nature05541.View ArticlePubMed
- Orazi A, Cattoretti G, Heerema NA, Sozzi G, John K, Neiman RS: Frequent p53 over expression in therapy related myelodysplastic syndromes and acute myeloid leukemia: an immunohistochemical study of bone marrow biopsies. Mod Pathol. 1993, 6: 521-5.PubMed
- Elghetany MT, Vyas S, Yuoh G: Significance of p53 overexpression in bone marrow biopsies from patients with bone marrow failure: aplastic anemia, hypocellular refractory anemia, and hypercellular refractory anemia. Ann Hematol. 1998, 77: 261-4. 10.1007/s002770050455.View ArticlePubMed
- Frisch B, Lewis M: The bone marrow in aplastic anaemia: Diagnostic and prognostic features. J clin Path. 1974, 27: 231-41. 10.1136/jcp.27.3.231.PubMed CentralView ArticlePubMed
- Cervenka J, Arthur D, Yasis C: Mitomycin C test for diagnostic differentiation of idiopathic aplastic anemia and Fanconi anemia. Pediatrics. 1981, 67 (1): 119-27.PubMed
- Basset-Seguin N, Molềs JP, Mils V, Dereure O, Guilhou JJ: TP53 tumor suppressor gene and skin carcinogenesis. J Invest Dermatol. 1994, 103 (5 Suppl): 102S-106S.View ArticlePubMed
- WU X, Bayle JH, Olson D, Levine AJ: The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993, 7 (7A): 1126-32. 10.1101/gad.7.7a.1126.View ArticlePubMed
- Chen J, Marechal V, Levine AJ: Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol. 1993, 13: 4107-14.PubMed CentralView ArticlePubMed
- Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM: Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem. 2000, 275: 45-8951.View Article
- Yan J, Jetten AM: RAP80 and RNF8, key players in the recruitment of repair proteins to DNA damage sites. Cancer Lett. 2008, 271: 179-90. 10.1016/j.canlet.2008.04.046.PubMed CentralView ArticlePubMed
- Wu Y, Brosh RM: FANCJ helicase operates in the Fanconi Anemia DNA repair pathway and the response to replicational stress. Laboratory of Molecular Gerontology, National Institute on Aging, NIH, NIH Biomedical Research Center, Baltimore, MD 21224, USA. 2009, 9 (4): 470-82.
- Nabhan SK, Bitencourt M, Duval M, Abecasis M, Dufour C, Boudjedir K, Rocha V, Socié G, Passweg J, Goi K, Sanders J, Snowden J, Yabe H, Pasquini R, Gluckman E: Fertility recovery and pregnancy after allogeneic hematopoietic stem cell transplantation in Fanconi anemia patients. Citation: Hematologica. 96: xxx-
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.